The Medicines Company (MDCO: NASDAQ)
$25.66 n/a | n/a%
10/30/14 - 03:59 PM ET
n/a / 687.90KVol / Avg. Vol:
n/a / 25.66Open / Prev. Close:
n/a - n/aToday's Range:
19.92 - 41.2852 Wk Range:
Portfolios with MDCO
- Portfolio NameUser Type
- ContributorToxic Stocks for the Week E...
- ContributorStocks Rising On Unusual Vo...
- UserGFNN Stockdiagnostics 3
- ContributorStocks At New 52-Week Highs...
- ContributorBreakout Stocks Of The Week...
- UserSUPRATRADE Top 10 Small Cap...
- Userdarrylb Portfolio 1
- Usermiamirocksters Portfolio 1
- ContributorBarron's Research Reports 4...
- UserPART 3 JPMorgan 27th Annual...
Latest MDCO Headlines from TheStreet
- Twitter Takes a Tumble as Ability to Innovate Comes into Question 10.28.14 | 12:10 pm
- Sell These 5 Toxic Stocks Before It's Too Late 08.15.14 | 07:08 am
- First Week of MDCO September 20th Options Trading 07.29.14 | 10:07 am
- Is antibiotic-resistant bacteria a curse or a blessing for Big Pharma? 07.09.14 | 10:07 am
- Top Swing Trade Ideas for Wednesday June 11: Facebook, Vivus, More 06.11.14 | 09:06 am
- Long Swing Picks After the Memorial Day Weekend: Isis, Tibco, More 05.27.14 | 11:05 am
- Today's Dead Cat Bounce Stock: Medicines Company (MDCO) 04.02.14 | 11:04 am
- The Medicines Company (MDCO): Today's Featured Drugs Laggard 04.01.14 | 05:04 pm
- 3 Stocks Underperforming Today In The Health Care Sector 04.01.14 | 01:04 pm
- The Medicines Company Stock Downgraded (MDCO) 03.31.14 | 11:03 am
Press Releases for MDCO
- The Medicines Company To Webcast Investor & Analyst Day On November 5 - Business Wire 10.30.14 | 04:10 pm
- The Medicines Company Announces Presentation Of Investigational Hemostatic Agent RAPLIXA™ (fibrin Sealant) Phase III FINISH-3 Trial Results At The 2014 Clinical Conference Of The American College Of Surgeons - Business Wire 10.28.14 | 11:10 am
- Alnylam And The Medicines Company Announce Filing Of A Clinical Trial Application To Initiate A Phase 1 Study For ALN-PCSsc, An Investigational, Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 For The Treatment Of Hypercholesterolemia - Business Wire 10.28.14 | 08:10 am
- The Medicines Company Wins Favorable Judgment In Angiomax® (Bivalirudin) Patent Litigation - Business Wire 10.27.14 | 08:10 pm
- The Medicines Company Announces Participation In 2014 American College Of Emergency Physicians Scientific Assembly - Business Wire 10.24.14 | 02:10 pm
- The Medicines Company Reports Third Quarter And First Nine Months 2014 Results - Business Wire 10.22.14 | 07:10 am
- ORBACTIVTM (Oritavancin) Phase 3 SOLO II Trial Results Published In The Journal Clinical Infectious Diseases - Business Wire 10.09.14 | 04:10 pm
- The Medicines Company To Announce Third Quarter 2014 Financial Results On Wednesday, October 22, 2014 - Business Wire 10.08.14 | 07:10 pm
- The Medicines Company Infectious Disease Portfolio Data To Be Presented At ID Week 2014 - Business Wire 10.06.14 | 02:10 pm
- The Medicines Company To Webcast Infectious Disease Care Investor & Analyst Day On September 24 - Business Wire 09.23.14 | 07:09 pm
Partner Headlines for MDCO
- Mylan Found to Have Infringed Medicines Co.'s Patent - Bloomberg 10.27.14 | 07:10 pm
- Bristol-Myers to Seek U.S. Approval for Immuno-Oncology Drug - Analyst Blog - Zacks 07.11.14 | 10:07 pm
- BIND Therapeutics Ends Oncology Deal with Amgen - Analyst Blog - Zacks 07.03.14 | 09:07 pm
- BioDelivery Progresses with Clonidine Late-Stage Study - Analyst Blog - Zacks 06.27.14 | 11:06 pm
- Medicines Co.'s Drug Fails to Win FDA Panel Backing - Bloomberg 02.12.14 | 03:02 pm
- Leaders Hold Near Buy Points Despite Monday Sell-Off - Investor's Business Daily 01.14.14 | 04:01 pm
- Update on MDCO's Pipeline - Analyst Blog - Zacks 12.27.13 | 10:12 pm
- Five Medical Stocks Leaders Trade Near New Highs - Investor's Business Daily 11.22.13 | 06:11 pm
- A Few Stocks Form Bases, But Have Flaws - Investor's Business Daily 11.20.13 | 06:11 pm
- Strong Pipeline Expected To Drive Growth At Medicines Co. - Investor's Business Daily 11.15.13 | 06:11 pm